A leading provider of
innovative DNA Screening solutions
IGH/FGFR3 Translocation, Dual Fusion LPH 030
The t(4;14) (p16.3;q32.3) translocation is found in approximately 10% of myeloma patients and results in the deregulation of at least two genes. These are MMSET (Multiple Myeloma SET domain containing protein also known as WHSC1) and FGFR3 (fibroblast growth factor receptor 3) with the formation of a fusion product between MMSET and the immunoglobulin heavy chain (IGH) locus and overexpression of FGFR3. It has been suggested that FGFR3 expression is switched on by close proximity to the strong enhancer elements in the immunoglobulin heavy chain.
IGH/FGFR3 Translocation, Dual Fusion
Cat. No. LPH 030-S (5 tests)
Cat. No. LPH 030 (10 tests)
- MM
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK